Osteopore Ltd (ASX: OSX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Osteopore Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Osteopore Ltd (ASX: OSX)
Latest News
Healthcare Shares
Osteopore (ASX:OSX) share price rockets 24% on major new deal
Share Market News
Osteopore (ASX:OSX) share price moving higher on distribution deal
⏸️ Investing
Why I think these small cap ASX shares will perform in 2021
Share Market News
ASX medical share surges 30% on development news
Share Market News
2 breakthrough ASX healthcare shares
⏸️ Investing
3 innovative ASX shares to buy
Share Market News
Osteopore share price storms 270% higher on distribution deal
OSX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Osteopore Ltd
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. Business operating segments are based on the firm's geographical presence in Singapore and Australia.
OSX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
21 Nov 2024 | $0.04 | $0.00 | 0.00% | 26,822 | $0.04 | $0.04 | $0.04 |
20 Nov 2024 | $0.04 | $0.00 | 0.00% | 176,869 | $0.04 | $0.04 | $0.04 |
19 Nov 2024 | $0.04 | $0.00 | 0.00% | 68,650 | $0.04 | $0.04 | $0.04 |
18 Nov 2024 | $0.04 | $0.00 | 0.00% | 307,124 | $0.04 | $0.04 | $0.04 |
15 Nov 2024 | $0.04 | $0.00 | 0.00% | 397,735 | $0.04 | $0.04 | $0.04 |
14 Nov 2024 | $0.04 | $0.00 | 0.00% | 393,667 | $0.04 | $0.04 | $0.04 |
13 Nov 2024 | $0.04 | $0.00 | 0.00% | 85,051 | $0.04 | $0.04 | $0.04 |
11 Nov 2024 | $0.04 | $0.00 | 0.00% | 1,844 | $0.04 | $0.04 | $0.04 |
08 Nov 2024 | $0.04 | $0.00 | 0.00% | 153,285 | $0.04 | $0.04 | $0.04 |
07 Nov 2024 | $0.04 | $0.00 | 0.00% | 315,860 | $0.04 | $0.04 | $0.04 |
06 Nov 2024 | $0.04 | $0.00 | 0.00% | 100,444 | $0.04 | $0.04 | $0.04 |
05 Nov 2024 | $0.04 | $0.00 | 0.00% | 170,955 | $0.04 | $0.04 | $0.04 |
04 Nov 2024 | $0.04 | $0.00 | 0.00% | 812,995 | $0.04 | $0.04 | $0.04 |
01 Nov 2024 | $0.04 | $0.00 | 0.00% | 74,350 | $0.04 | $0.04 | $0.04 |
31 Oct 2024 | $0.04 | $0.00 | 0.00% | 177,935 | $0.04 | $0.04 | $0.04 |
30 Oct 2024 | $0.04 | $0.00 | 0.00% | 32,394 | $0.04 | $0.04 | $0.04 |
29 Oct 2024 | $0.04 | $0.00 | 0.00% | 26,122 | $0.04 | $0.04 | $0.04 |
28 Oct 2024 | $0.04 | $0.00 | 0.00% | 107,070 | $0.04 | $0.04 | $0.04 |
25 Oct 2024 | $0.04 | $0.00 | 0.00% | 388,629 | $0.04 | $0.04 | $0.04 |
24 Oct 2024 | $0.04 | $0.00 | 0.00% | 223,753 | $0.04 | $0.04 | $0.04 |
23 Oct 2024 | $0.04 | $0.00 | 0.00% | 12,200 | $0.04 | $0.04 | $0.04 |
22 Oct 2024 | $0.04 | $0.00 | 0.00% | 102,426 | $0.04 | $0.04 | $0.04 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
08 May 2024 | Mark Leong | Issued | 25,000 | $3,125 |
Rights issue.
|
08 May 2024 | Mark Leong | Issued | 125,000 | $3,625 |
Rights issue.
|
08 May 2024 | Swee Hin Teoh | Issued | 584,897 | $16,962 |
Rights issue.
|
08 May 2024 | Swee Hin Teoh | Issued | 116,979 | $14,622 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Mark Kei Wei Leong | Executive ChairmanExecutive Director | Aug 2021 |
Mr Leong has corporate, management and directorship experience in a range of functions in a diverse range of industries having undertaken several C suite roles (CEO, COO, & CFO) in several private as well as listed companies. He Holds Directorships as Non Executive Director of MDR Limited (SGX:Y3D), Non Executive Director of HS Optimus Holdings Limited (SGX:504), Non Executive Director of 9R Limited (SGX:1Y1) Non Executive Director of LMIRT Management Ltd (SGX:D5IU), Non Executive Director of CytoMed Therapeutics Limited (NASDAQ: GDTC). He held directorships Non Executive Director of LCT Holdings Limited (SGX: delisted December 2020) Executive Director of LifeBrandz Ltd (SGX: 1D3).
|
Professor Swee Hin Teoh | Non-Executive Director | Jun 2019 |
Mr Teoh is currently the Founding Director and Distinguished Yule Chair Professor, Center for Advanced Medical Engineering (CAME) at the College of Materials Science and Engineering, Hunan University, China. He is Emeritus Professor at School of Chemical and Biomedical Engineering (SCBE) and held joint appointment with the Lee Kong Chian School of Medicine (LKC Med) at Nanyang Technological University (NTU). His contribution is in the development and clinical translation of 3D bioresorbable scaffolds. his research journey focused on translating the materials research to biomedical benefits. He is a Fellow of the Academy of Engineers Singapore and Chief Engineer at Skin Research Institute of Singapore. His research focused on the study of mechanisms that promote cells proliferation and differentiation as a result of mechano induction through load bearing scaffolds for tissue regeneration and remodelling. Presently, he focuses on regenerative medicine research from tissue engineering bone and skin to biomimetic bioreactors to fish collagen, decellularized organs and others. With more than 37 PhDs, 270 research publications and 22 patents and technical disclosures, he is a forerunner and excellent educator in bioengineering and research scientist in translational regenerative medicine.
|
Mr Daniel Ow | Non-Executive Director | Oct 2021 |
Mr Ow has accumulated more than twenty years of international experience spanning various industries, such as infrastructure, resources, property, and fast moving consumer goods. Throughout his career, he has undertaken several finance and management positions within multinational corporations. Presently, Mr Ow holds the role of Chief Financial Officer at Greenpool Capital, a fully integrated property investment, asset, and development firm. In addition to his professional endeavors, he has also served as a Trustee Director on the Rio Tinto Staff Superannuation Fund, which has since merged with Equip Super.
|
Hon Michael Keenan | Non-Executive Director | Jul 2023 |
Mr Keenan is a former Australian Government Cabinet Minister and brings invaluable expertise in public policy and corporate governance. He served as a Federal Member of Parliament from 2004 to 2019, holding senior ministry positions in the Abbott, Turnbull, and Morrison Governments between 2013 to 2019. His ministerial portfolios included Human Services, where he provided direction and oversight of Medicare, as well as Justice, Counter Terrorism, and Digital Transformation. Notably, Mr. Keenan also serves on the Board of U Group and Co, as well as the Australian Strategic Policy Institute.
|
Dr Yujing Lim | Chief Executive OfficerExecutive Director | Jul 2023 |
--
|
Mr Jack Rosagro | Company Secretary | May 2024 |
-
|
Jack Rosagro | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Pty Limited | 989,564 | 9.58% |
Bnp Paribas Noms Pty Ltd Uobkh A/C R'Miers | 703,551 | 6.81% |
Ms Irene Ng Ai Chen | 658,833 | 6.38% |
Mr Patrick John Mchale | 500,000 | 4.84% |
Hsbc Custody Nominees (Australia) Limited | 328,433 | 3.18% |
Mr Michael Marcus Liew | 301,730 | 2.92% |
Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> | 297,624 | 2.88% |
Ching Yuan Huang | 280,769 | 2.72% |
Lim Thiam Chye | 245,116 | 2.37% |
Dietmar Hutmacher | 214,234 | 2.07% |
Bnp Paribas Noms Pty Ltd | 212,939 | 2.06% |
Ho Chwan Investment Co Ltd | 210,577 | 2.04% |
Mr Hanry Yu | 210,371 | 2.04% |
Dr Russell Kay Hancock | 200,000 | 1.94% |
Merrill Lynch (Australia) Nominees Pty Limited | 170,278 | 1.65% |
Mr Kelvin Chua Yong Wei | 165,883 | 1.61% |
Mr Lim Jing | 157,334 | 1.52% |
Annika Walter Schantz | 139,800 | 1.35% |
Bnp Paribas Noms Pty Ltd Uob Kh Pl Ac | 104,451 | 1.01% |
Round Table Partners Berhad | 102,300 | 0.99% |